Want to join the conversation?
$ADMS said the phase 3 EASE LID trial results showed a 23% reduction in levodopa-induced dyskinesia (LID) for ADS-5102-treated patients compared to placebo. The reduction in LID was maintained at 24 weeks, a key secondary analysis. $ADMS plans to present comprehensive data at an upcoming scientific conference.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!